Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SCTB35 in systemic lupus erythematosus
CTR20244176Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB35 in systemic lupus erythematosus (SLE), sponsored by Sinocelltech Group Limited. Started Jan 2025; status: active.
02
Drugs
SCTB35
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20244176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244176.